EUVIMEDEUVIMED entdecken
Crossref

Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry

Aikaterini Michalopoulou iD, Susanna Ranta iD, Nadine G Andersson iD, Kathelijn Fischer iD, Marloes de Kovel iD, Elsbeth de Boer-Verdonk, Jayashree Motwani iD, Gili Kenet iD, Helen Pergantou iD

Haemophilia · 2025

DOI: 10.1111/hae.70140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Aikaterini Michalopoulou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia Centre/Haemostasis and Thrombosis Unit, Aghia Sophia Children's Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Hemophilia A, Joints, Hemarthrosis, Joint Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: PedNet Hemophilia Research Foundation Grant, Bayer AG, Novo Nordisk Healthcare AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Different strategies in prophylaxis for haemophilia among countries may affect long‐term outcome.

Aim

The aim of this study is to compare joint health in persons with severe haemophilia (PwSH) between Sweden and Greece, based on different approaches on prophylaxis initiation and management.

Methods

Data were extracted from the PedNet Registry, which collects patient data prospectively, regarding measures on treatment and joint health using Haemophilia Joint Health Score (HJHS) and Haemophilia Early Arthropathy Detection with Ultrasound (HEAD‐US).

Results

Sixty‐one Swedish and 51 Greek PwSH (aged ≥ 10–18 years) were included. Swedish adolescents were diagnosed at earlier age (0.53 vs. 0.77 years in Greece, p < 0.01). At prophylaxis initiation {earlier in Sweden ( p < 0.01)}, dose regimens were more intense and escalation to full prophylaxis was reached earlier in Sweden. Median age at the last HEAD‐US was 15.82 versus 14.07 years and at the last HJHS: 15.26 versus 15.86 years, for Sweden and Greece, respectively. Swedish and Greek PwSH had similar median total HJHS: 1.5 versus 1.0, respectively, p = 0.38. Based on HEAD‐US, signs of synovitis were less frequent in Sweden for ankles (31.1% vs. 72.2%; p < 0.01), knees (11.1% vs. 44.4%, p < 0.01) and elbows (8.9% vs. 27.8%, p < 0.05). Bone/cartilage abnormalities were also less frequent in Swedish patients (ankles: 11.1% vs. 30.6%; p < 0.05, knees: 6.7% vs. 11.1%; p = 0.69, elbows: 8.9% vs. 19.4%; p = 0.20).

Conclusion

Although adolescent PwSH clinically have good joint health in both countries, differences were detected by HEAD‐US, with earlier prophylaxis in Sweden being associated with better joint outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AJointsHemarthrosisJoint DiseasesHumansAdolescentSwedenRegistriesChildMaleGreeceUltrasonographyFemale

Stichwörter der Autor:innen

HEAD‐USHJHSarthropathyhaemophiliapaediatrics

Autor:innen und Institutionen

  • Haemophilia Centre/Haemostasis and Thrombosis Unit, Aghia Sophia Children's Hospital, Athens, Greece.
  • Department of Women's and Children's Health, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden, and Childhood Cancer Research Unit, Karolinska, Institutet, Stockholm, Sweden.
  • Center For Thrombosis and Haemostasis, Sweden and Department of Clinical Sciences and Paediatrics, Skåne University Hospital, Malmö, Lund University, Lund, Sweden.
  • Van Creveld Kliniek, University Medical Center Utrecht, Utrecht, The Netherlands; PedNet Haemophilia Research Foundation, Baarn, the Netherlands.
  • PedNet Haemophilia Research Foundation, Baarn, the Netherlands.
  • Department of Haematology, Haemophilia Comprehensive Care Centre, Birmingham Children's Hospital, Birmingham, UK.

ORCID-Profile: Aikaterini Michalopoulou, Susanna Ranta, Nadine G Andersson, Kathelijn Fischer, Marloes de Kovel, Jayashree Motwani, Gili Kenet, Helen Pergantou

Förderung

  • PedNet Hemophilia Research Foundation Grant
  • Bayer AG
  • Novo Nordisk Healthcare AG
  • CSL Behring GmbH
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Hoffmann-La Roche
  • LFB Biotechnologies

Zitieren

APA

Michalopoulou, A., Ranta, S., Andersson, N. G., Fischer, K., de Kovel, M., de Boer-Verdonk, E., Motwani, J., Kenet, G., & Pergantou, H. (2025). Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry. Haemophilia. https://doi.org/10.1111/hae.70140

Vancouver

Michalopoulou A, Ranta S, Andersson NG, Fischer K, de Kovel M, de Boer-Verdonk E, et al. Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry. Haemophilia. 2025. doi:10.1111/hae.70140

BibTeX
@article{Michalopoulou2025,
  author = {Michalopoulou, Aikaterini and Ranta, Susanna and Andersson, Nadine G and Fischer, Kathelijn and de Kovel, Marloes and de Boer-Verdonk, Elsbeth and Motwani, Jayashree and Kenet, Gili and Pergantou, Helen},
  title = {Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70140}
}
Kostenlos starten →